Compare GE Vernova Inc (GEV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

GE Vernova (GEV) trades at $1,004.73, up 0.77% with strong bullish technical momentum. The stock shows exceptional profitability with 23.04% net margins and 91.48% ROE, though valuation appears elevated with P/E of 28.65. Recent Q2 2026 earnings missed expectations, but Q1 and Q4 2025 results significantly beat forecasts. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.

Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target representing 26% upside. Key risks include execution challenges in wind segment and valuation concerns. Strong backlog growth to $176 billion and AI power demand create substantial growth runway, though investors should monitor margin expansion and competitive pressures.

Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.

Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.